HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Primary medulloepithelioma — Clinical Guidelines

Overview

Primary central nervous system vasculitis (PCNSV) is a rare inflammatory condition affecting medium- and small-calibre blood vessels within the central nervous system, often presenting with neurological deficits and mimicking other pathologies like tumors or hemorrhages 1 2 6 10.

Diagnosis

Clinical Presentation: Variable, including headache, hemiparesis, altered cognition, and tumor-like masses 6 10.

Imaging: Contrast-enhanced MRI, perfusion MRI, and 1H-MRS can help distinguish PCNSV from glioblastoma 4.

Histopathological Confirmation: Essential; brain/spinal cord biopsy is crucial for definitive diagnosis 1 5 9.

Endothelial Cells: Elevated circulating endothelial cells may serve as a potential biomarker 9.

Angiography: Often used but not specific or sensitive 5.

Differential Diagnosis: Important to rule out mimics such as brain tumors and spinal subdural hematoma 6 10.

Management

First-Line Treatment: Corticosteroids and immunosuppressants (specific drugs not detailed in abstracts) 1 3.

Adjunctive Therapy: Tocilizumab, an anti-interleukin-6 monoclonal antibody, shows promise in refractory cases 3.

Monitoring and Response: Evaluate treatment response clinically and radiologically 3.

Special Populations

Pediatrics: Radiation-induced late brain injuries, including microbleeds and cavernomas, warrant consideration post-radiotherapy 8.

Elderly: No specific details provided in abstracts.

Comorbidities: No specific guidance provided in abstracts regarding comorbidities.

Key Recommendations

Histopathological Confirmation is Essential for Diagnosis (Evidence: Strong 1 5).

Use Contrast-Enhanced MRI and Other Advanced Imaging Techniques for Differentiation (Evidence: Moderate 4).

Consider Biopsy Early to Avoid Delayed Diagnosis (Evidence: Expert opinion 9).

Refractory Cases May Benefit from Tocilizumab (Evidence: Weak 3).

Monitor Treatment Response Closely (Evidence: Expert opinion).

References

1 Rice C, Scolding N. Primary central nervous system vasculitis: an update. Journal of neurology 2026. link 2 Ruiz-Nieto N, Aparicio-Collado H, Segura-Cerdá A, Barea-Moya L, Zahonero-Ferriz A, Campillo-Alpera MS et al.. Primary central nervous system vasculitis: A diagnostic and therapeutic challenge. A series of 7 patients. Neurologia 2024. link 3 Cabreira V, Dias L, Fernandes B, Aires A, Guimarães J, Abreu P et al.. Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience. Acta neurologica Scandinavica 2022. link 4 Kawazoe Y, Ohba S, Murayama K, Nakae S, Nishiyama Y, Abe M et al.. Contrast-Enhanced Magnetic Resonance Imaging, Perfusion Magnetic Resonance Imaging, and 1H-Magnetic Resonance Spectroscopy Distinguish Primary Central Nervous System Vasculitis from Glioblastoma. World neurosurgery 2022. link 5 Rice CM, Scolding NJ. The diagnosis of primary central nervous system vasculitis. Practical neurology 2020. link 6 Salvarani C, Brown RD, Christianson TJH, Huston J, Morris JM, Giannini C et al.. Primary central nervous system vasculitis mimicking brain tumor: Comprehensive analysis of 13 cases from a single institutional cohort of 191 cases. Journal of autoimmunity 2019. link 7 Kon T, Funamizu Y, Suzuki C, Sato T, Kurotaki H, Kurihara A et al.. A Long Interval from a Spinal Cord Lesion to a Subsequent Brain Lesion in Primary Central Nervous System Vasculitis. Internal medicine (Tokyo, Japan) 2019. link 8 Passos J, Nzwalo H, Valente M, Marques J, Azevedo A, Netto E et al.. Microbleeds and cavernomas after radiotherapy for paediatric primary brain tumours. Journal of the neurological sciences 2017. link 9 Deb-Chatterji M, Gerdes S, Heeren M, Lambrecht J, Worthmann H, Goldbecker A et al.. Circulating endothelial cells as potential diagnostic biomarkers in primary central nervous system vasculitis. Journal of neurology, neurosurgery, and psychiatry 2013. link 10 Fu M, Omay SB, Morgan J, Kelley B, Abbed K, Bulsara KR. Primary central nervous system vasculitis presenting as spinal subdural hematoma. World neurosurgery 2012. link 11 Salvarani C, Brown RD, Calamia KT, Christianson TJ, Huston J, Meschia JF et al.. Rapidly progressive primary central nervous system vasculitis. Rheumatology (Oxford, England) 2011. link

Primary medulloepithelioma